09:26 AM EST - Oncolytics Biotech Inc : Today announced recent operational highlights and financial results for the third quarter ended September 30, 2023. Highlights include; Phase 1/2 survival data from GOBLET pancreatic cancer cohort demonstrates improvements over historical control trials; Award and grant funding from Pancreatic Cancer Action Network (PanCAN) provides financial boost and will enable further evaluation of pelareorep in pancreatic cancer;
Cash position stands at $40.0 million with a projected cash runway through critical milestones, including BRACELET-1 survival data. Oncolytics Biotech Inc
shares T.ONC are trading unchanged at $2.43.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=5094315298132924
